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Abstract
Background: Secondary hyperparathyroidism (SHPT) is associated with adverse outcomes in patients receiving
maintenance dialysis. Parathyroidectomy is a treatment for SHPT; whether parathyroidectomy utilization varies
geographically in the US is unknown.
Methods: A retrospective cohort analysis was undertaken to identify all patients aged 18 years or older who were
receiving in-center hemodialysis between 2007 and 2009, were covered by Medicare Parts A and B, and had been
receiving hemodialysis for at least 1 year. Parathyroidectomy was identified from inpatient claims using relevant
International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes. Patient characteristics and
End-Stage Renal Disease Network (a proxy for geography) were ascertained. Adjusted odds ratios for parathyroidectomy
were estimated from a logistic model.
Results: A total of 286,569 patients satisfied inclusion criteria, of whom 4435 (1.5%) underwent PTX. After adjustment for
a variety of patient characteristics, there was a 2-fold difference in adjusted odds of parathyroidectomy between the
most- and least-frequently performing regions. Adjusted odds ratios were more than 20% higher than average in four
networks, and more than 20% lower in four networks.
Conclusions: Parathyroidectomy use varies substantially by geography in the US; the factors responsible should be
further investigated.
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Background
Secondary hyperparathyroidism (SHPT) is associated
with adverse outcomes in patients receiving mainten-
ance dialysis [1, 2]. Anecdotally, physicians appear to
have widely variable criteria regarding which patients
they choose to refer for parathyroidectomy, at least in
the US. Perhaps reflecting uncertainty over its role,
rates of parathyroidectomy have changed substantially
over time in recent decades [3]. While guidelines rec-
ommend parathyroidectomy in patients with severe
SHPT [4], how it might be used most optimally is
uncertain. Parathyroidectomy has been shown to be
associated with improved outcomes in some studies
[5, 6]; however, it has also been shown to be associ-
ated with mortality, protracted hypocalcemia, and
over-suppression of parathyroid hormone (PTH) [7],
and its results with regard to mineral metabolic con-
trol are often suboptimal [8]. Thus, understanding the
differences between hemodialysis patients who do and
do not undergo parathyroidectomy may be important.
However, the effect of geographic variation, which is
associated with a variety of outcomes and care differ-
ences in the dialysis population [9, 10] has not been
examined in the context of parathyroidectomy. We
therefore conducted a retrospective cohort study to
examine whether parathyroidectomy use varies geo-
graphically in the United States.
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Methods
Using the United States Renal Data System end-stage
renal disease database, we identified patients aged 18
years or older who were receiving in-center hemo-
dialysis between 2007 and 2009, were covered by
Medicare Part A (inpatient, outpatient, skilled nursing
facility, hospice, or home health agency) and Part B
(physician/supplier) as primary payer, and had been
receiving hemodialysis for at least 1 year. Parathy-
roidectomy was identified from inpatient claims using
International Classification of Diseases, Ninth Revision,
Clinical Modification procedure codes 06.81 (complete
parathyroidectomy), 06.89 (partial parathyroidectomy and
parathyroidectomy not otherwise specified), and 06.95
(parathyroid tissue reimplantation).
Patient characteristics, derived from the end-stage
renal disease database Medical Evidence Report and
Medicare claims, were assessed on the parathyroidec-
tomy date and on January 1 for non-parathyroidectomy
patients. Characteristics included age, sex, race, body
mass index, cause of renal disease, dialysis duration, and
common comorbid conditions, as have been used previ-
ously [11]. Our proxy for geography was US End-Stage
Renal Disease Network (n = 18, Table 1), geographically
based regions designed to facilitate care and monitor
quality on a regional level. Adjusted odds ratios (ORs)
and 95% confidence intervals (CIs) for parathyroidec-
tomy were estimated from a logistic model adjusting for
the factors described above. The adjusted ORs for the
renal networks were calculated using the whole nation
as the reference. All statistical analyses were conducted
using SAS software, Version 9.2, SAS Institute Inc., Cary,
NC, USA.
Results
We identified 286,569 patients who satisfied our
inclusion criteria, of whom 4435 (1.5%) underwent
parathyroidectomy (Table 2). Parathyroidectomy fre-
quency was 2.3 fold greater, in unadjusted terms, for
the least-frequently performing region (0.97% of
patients, Network 18) compared with the most-
frequently performing region (2.20% of patients,
Network 6).
Network was associated with substantial variability
in likelihood of parathyroidectomy (Fig. 1). Even after
adjustment for all characteristics in Table 2, adjusted
ORs for parathyroidectomy varied from 0.67 (95% CIs
0.58–0.78) to 1.37 (1.17–1.60) between the least- and
most-frequently performing regions. Adjusted ORs
were more than 20% higher than the national level in
four networks and more than 20% lower in four
networks.
In addition, younger age (adjusted OR 1.95, 95% CI 1.83–
2.08, vs. age 45–64 years), female sex (1.23, 1.16–1.30),
black race (1.29, 1.21–1.37 vs. white), dialysis duration > 5
years (3.70, 3.27–4.05 vs. 1- < 3 years), and atherosclerotic
heart disease (1.15, 1.07–1.23) were associated with para-
thyroidectomy (P < 0.001). Diabetes (0.82, 0.76–0.89) and
history of stroke (0.82, 0.74–0.89) were inversely associated
with parathyroidectomy.
Results for the multivariable model for factors associ-
ated with parathyroidectomy are shown in Table 3.
Discussion
SHPT treatment presents a complex clinical chal-
lenge. Practice guidelines provide direction [4] but
suffer from lack of randomized clinical trial data,
resulting in uncertainty about the benefits and risks
of parathyroidectomy. Understanding use of parathy-
roidectomy is important, given widely varying recent
data demonstrating both clinical benefits [5, 6], as
well as high rates of adverse events and suboptimal
mineral metabolic outcomes [7, 8]. Our large retro-
spective analysis demonstrated substantial geographic
variation in parathyroidectomy use. This difference
was not driven solely by outliers at the extremes;
AORs were 20% higher or lower than unity in eight
Networks. This could reflect regional differences in
many potential factors, including provider-related
Table 1 End-stage renal disease networks and associate US states
Network number States and territories
1 Connecticut, Maine, Massachusetts, New Hampshire,
Rhode Island, Vermont
2 New York
3 New Jersey, Puerto Rico, Virgin Islands
4 Delaware, Pennsylvania
5 District of Columbia, Maryland, Virginia, West Virginia
6 Georgia, North Carolina, South Carolina
7 Florida
8 Alabama, Mississippi, Tennessee
9 Indiana, Kentucky, Ohio
10 Illinois
11 Michigan, Minnesota, North Dakota, South Dakota,
Wisconsin
12 Iowa, Kansas, Missouri, Nebraska
13 Arkansas, Louisiana, Oklahoma
14 Texas
15 Arizona, Colorado, Nevada, New Mexico, Utah,
Wyoming
16 Alaska, Idaho, Montana, Oregon, Washington
17 American Samoa, Guam, Mariana Islands, Hawaii,
Northern California
18 Southern California
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Table 2 Characteristics of patients who did and did not undergo parathyroidectomy
PTX Non-PTX
n % n %
Total 4435 100 282,134 100
Age at PTX, years
19–44 1764 39.8 38,830 13.8
45–64 2154 48.6 110,788 39.3
65–74 410 9.2 69,550 24.7
≥ 75 107 2.4 62,966 22.3
Race
White 1685 38.0 156,638 55.5
Black 2551 57.5 108,246 38.4
Other 199 4.5 17,250 6.1
Sex
Male 2298 51.8 155,257 55.0
Female 2137 48.2 126,877 45.0
ESRD primary cause
Diabetes 1013 22.8 128,202 45.4
Hypertension 1462 33.0 81,231 28.8
Glomerulonephritis 934 21.1 27,250 9.7
Other/unknown/missing 1026 23.1 45,451 16.1
BMI, kg/m2
< 18 151 3.4 8074 2.9
18– < 25 1217 27.4 88,838 31.5
25– < 30 1026 23.1 78,938 28.0
30– < 35 772 17.4 49,310 17.5
35– < 40 517 11.7 25,987 9.2
≥ 40 536 12.1 23,383 8.3
Missing 216 4.9 7604 2.7
Dialysis duration, years
1– < 3 538 12.1 151,778 53.8
3– < 5 970 21.9 58,341 20.7
> 5 2927 66.0 72,015 25.5
Comorbidities
Diabetes 1954 44.1 185,029 65.6
ASHD 1542 34.8 131,678 46.7
CHF 1973 44.5 144,792 51.3
CVA/TIA 522 11.8 57,532 20.4
PVD 1389 31.3 112,972 40.0
Dysrhythmia 1057 23.8 77,320 27.4
Other cardiac disease 1623 36.6 91,955 32.6
Network
1 151 3.4 9407 3.3
2 192 4.3 16,808 6.0
3 156 3.5 11,887 4.2
4 118 2.7 11,689 4.1
5 260 5.9 17,080 6.1
6 667 15.0 29,663 10.5
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ones such as particular treatment approaches instilled
during training, access to qualified parathyroid sur-
geons, or local “cultures” of treatment, all of which
might play substantial roles in how care is differen-
tially rendered [12].
Certain demographic factors, specifically younger age
and black race, were also associated with likelihood of
parathyroidectomy; this was not unexpected given that
both of these factors have been previously reported to be
associated with more severe SHPT [2, 13]. Dialysis dur-
ation was also associated with parathyroidectomy, pos-
sibly because the changes that characterize severe
parathyroid gland dysregulation may take many years to
develop [14]; alternatively, providers may be resorting to
parathyroidectomy only after prolonged attempts at
other interventions prove fruitless. The inverse associa-
tions between older age and history of stroke and para-
thyroidectomy may reflect poor surgical candidacy in
the provider’s estimation.
Our study was limited by lack of patient-level data
about degree of PTH control, SHPT therapies employed,
or other SHPT markers such as serum calcium and
phosphorus, which likely predict the parathyroidectomy
decision. For example, use of cinacalcet, which has been
shown to reduce rates of parathyroidectomy [15], might
vary widely by region, although we have no a priori rea-
son to posit this and it seems unlikely to account for a
more than 2-fold variation in parathyroidectomy rates.
Additionally, we lack information about geographic vari-
ation in renal transplant; fewer individuals in areas in
which early transplant occurs more commonly might be
at risk of developing severe SHPT and subsequently
undergoing parathyroidectomy. Again, given the magni-
tude of variation between the most- and least-frequently
parathyroidectomy performing regions, case mix alone is
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Fig. 1 Odds ratios for factors associated with parathyroidectomy.
ASHD, atherosclerotic heart disease; CHF, congestive heart failure;
CVA, cerebrovascular accident; ESRD, end-stage renal disease; PVD,
peripheral vascular disease
Table 2 Characteristics of patients who did and did not undergo parathyroidectomy (Continued)
7 253 5.7 16,076 5.7
8 364 8.2 17,060 6.1
9 293 6.6 21,152 7.5
10 154 3.5 11,977 4.3
11 252 5.7 18,814 6.7
12 199 4.5 11,188 4.0
13 254 5.7 12,073 4.3
14 487 11.0 27,892 9.9
15 182 4.1 12,016 4.3
16 139 3.1 7254 2.6
17 136 3.1 11,860 4.2
18 178 4.0 18,238 6.5
ASHD atherosclerotic heart disease, BMI body mass index, CHF congestive heart failure, CVA/TIA cerebrovascular accident/transient ischemic attack, ESRD end-stage renal
disease, PTX parathyroidectomy, PVD peripheral vascular disease
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Conclusion
Even after adjustment of a variety of case-mix variables,
use of parathyroidectomy varies substantially by geog-
raphy in the US; the factors responsible should be
further investigated. Given recent information about the
potential risks associated with parathyroidectomy [7, 8],
the factors responsible for shaping the decision to
undertake it should also be the subject of future
investigation.
Abbreviations
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Table 3 Multivariable model for factors associated with
parathyroidectomy
Factors HR (95% CI) P
Age at PTX, years
19–44 1.95 (1.83–2.08) <0.001
45–64 1 (Referent)
65–74 0.37 (0.34–0.42) < 0.001
≥ 75 0.11 (0.09–0.13) < 0.001
Race
White 1 (Referent)
Black 1.29 (1.21–1.37) < 0.001
Other 0.89 (0.77–1.03) 0.11
Sex
Male 0.82 (0.77–0.87) < 0.001
Female 1 (Referent)
ESRD primary cause
Diabetes 0.58 (0.53–0.64) < 0.001
Hypertension 1 (Referent)
Glomerulonephritis 1.11 (1.02–1.21) 0.011
Other/unknown/missing 1.04 (0.96–1.13) 0.30
BMI, kg/m2
< 18 0.96 (0.82–1.13) 0.62
18– < 25 1 (Referent)
25– < 30 1.10 (1.02–1.20) 0.016
30– < 35 1.32 (1.21–1.44) < 0.001
35– < 40 1.48 (1.34–1.64) < 0.001
≥ 40 1.53 (1.38–1.69) < 0.001
Missing 1.08 (0.94–1.24) 0.29
Dialysis duration, years
1– < 3 1 (Referent)
3– < 5 2.23 (2.02–2.47) < 0.001
≥ 5 3.70 (3.37–4.05) < 0.001
Comorbid conditions
Diabetes 0.82 (0.76–0.89) < 0.001
ASHD 1.15 (1.07–1.23) < 0.001
CHF 1.08 (1.01–1.15) 0.019
CVA/TIA 0.82 (0.74–0.89) < 0.001
PVD 0.97 (0.91–1.04) 0.42
Dysrhythmia 1.08 (1.00–1.16) 0.058
Other cardiac disease 1.37 (1.29–1.47) < 0.001
ESRD Network
16 1.37 (1.17–1.60) < 0.001
1 1.35 (1.17–1.57) < 0.001
12 1.24 (1.09–1.40) 0.001
13 1.24 (1.08–1.37) 0.001
6 1.18 (1.09–1.28) < 0.001
Table 3 Multivariable model for factors associated with
parathyroidectomy (Continued)
8 1.17 (1.06–1.29) 0.002
15 1.14 (0.99–1.31) 0.067
14 1.13 (1.03–1.23) 0.008
11 1.03 (0.92–1.16) 0.60
7 1.01 (0.90–1.13) 0.91
3 0.97 (0.84–1.12) 0.69
9 0.92 (0.83–1.02) 0.12
5 0.88 (0.79–0.99) 0.032
10 0.88 (0.76–1.01) 0.070
17 0.80 (0.68–0.93) 0.005
2 0.78 (0.68–0.88) < 0.001
4 0.69 (0.59–0.82) < 0.001
18 0.67 (0.58–0.78) < 0.001
Year
2007 1 (Referent)
2008 0.89 (0.83–0.95) 0.001
2009 0.83 (0.78–0.89) < 0.001
ASHD atherosclerotic heart disease, BMI body mass index, CHF congestive heart
failure, CI confidence interval, CVA/TIA cerebrovascular accident/transient ischemic
attack, ESRD end-stage renal disease, HR hazard ratio, PTX parathyroidectomy,
PVD peripheral vascular disease
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